Iodothyronine deiodinase

In tissues, deiodinases can either activate or inactivate thyroid hormones:

• Activation occurs by conversion of the prohormone thyroxine (T₄) to the active hormone triiodothyronine (T₃) through the removal of an iodine atom on the outer ring.
• Inactivation of thyroid hormones occurs by removal of an iodine atom on the inner ring, which converts thyroxine to the inactive reverse triiodothyronine (rT₃), or which converts the active triiodothyronine to diiodothyronine (T₂).

The major part of thyroxine deiodination occurs within the cells.

Deionidase 2 activity can be regulated by ubiquitination:

• The covalent attachment of ubiquitin inactivates D2 by disrupting dimerization and targets it to degradation in the proteosome.[7]
• Deubiquitination removing ubiquitin from D2 restores its activity and prevents proteosomal degradation.[7]
• The Hedgehog cascade acts to increase D2 ubiquitination through WSB1 activity, decreasing D2 activity.[7][8]

D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T₄ to T₃, providing some though minimal therapeutic effect.

The three deiodinase enzymes share certain structural features in common although their sequence identity is lower than 50%. Each enzyme weighs between 29 and 33kDa.[7] Deiodinases are dimeric integral membrane proteins with single transmembrane segments and large globular heads (see below).[9] They share a TRX fold that contains the active site including the rare selenocysteine amino acid and two histidine residues.[7][10] Selenocysteine is coded by a UGA codon, which generally signifies termination of a peptide through a stop codon. In point mutation experiments with Deiodinase 1 changing UGA to the stop codon TAA resulted in a complete loss of function, while changing UGA to cysteine (TGT) caused the enzyme to operate at around 10% normal efficiency.[11] In order for UGA to be read as a selenocysteine amino acid instead of a stop codon, it is necessary that a downstream stem loop sequence, the selenocysteine insertion sequence (SECIS), be present to bind with SECIS binding protein-2 (SBP-2), which binds with elongation factor EFsec.[7] The translation of selenocysteine is not efficient,[12] even though it is important to the functioning of the enzyme. Deiodinase 2 is localized to the ER membrane while Deiodinase 1 and 3 are found in the plasma membrane.[7]

The related catalytic domains of Deiodinases 1-3 feature a thioredoxine-related peroxiredoxin fold.[13] The enzymes catalyze a reductive elimination of iodine, thereby oxidizing themselves similar to Prx, followed by a reductive recycling of the enzyme.

In most vertebrates, there are three types of enzymes that can deiodinate thyroid hormones:

Deiodinase 1 both activates T₄ to produce T₃ and inactivates T₄. Besides its increased function in producing extrathyroid T₃ in patients with hyperthyroidism, its function is less well understood than D2 or D3 [2][7] Deiodinase 2, located in the ER membrane, converts T₄ into T₃ and is a major source of the cytoplasmic T₃ pool.[2] Deiodinase 3 prevents T₄ activation and inactivates T₃.[9] D2 and D3 are important in homeostatic regulation in maintaining T₃ levels at the plasma and cellular levels. In hyperthyroidism D2 is down regulated and D3 is upregulated to clear extra T₃, while in hypothyroidism D2 is upregulated and D3 is downregulated to increase cytoplasmic T₃ levels.[2][7]

Serum T₃ levels remain fairly constant in healthy individuals, but D2 and D3 can regulate tissue specific intracellular levels of T₃ to maintain homeostasis since T₃ and T₄ levels may vary by organ. Deiodinases also provide spatial and temporal developmental control of thyroid hormone levels. D3 levels are highest early in development and decrease over time, while D2 levels are high at moments of significant metamorphic change in tissues. Thus D2 enables production of sufficient T₃ at necessary time points while D3 may shield tissue from overexposure to T₃.[12]

Also, iodothyronine deiodinases (type 2 y 3; DIO2 and DIO3, respectively) respond to seasonal changes in photoperiod-driven melatonin secretion and govern peri-hypothalamic catabolism of the prohormone thyroxine (T4). In long summer days, the production of hypothalamic T3 increase due to DIO-2-mediated conversion of T4 to the biologically active hormone. This process allows to active anabolic neuroendocrine pathways that maintain reproductive competence and increase body weight. However, during the adaptation to reproductively inhibitory photoperiods, the levels of T3 decrease due to peri-hypothalamic DIO3 expression that catabolizes T4 and T3 into receptor inactive amines.[17][18]

Deiodinase 2 also plays a significant role in thermogenesis in brown adipose tissue (BAT). In response to sympathetic stimulation, dropping temperature, or overfeeding BAT, D2 increases oxidation of fatty acids and uncouples oxidative phosphorylation via uncoupling protein, causing mitochondrial heat production. D2 increases during cold stress in BAT and increases intracellular T₃ levels. In D2 deficient models, shivering is a behavioral adaptation to the cold. However, heat production is much less efficient than uncoupling lipid oxidation.[19][20]

In cardiomyopathy the heart reverts to a fetal gene programming due to the overload of the heart. Like during fetal development, thyroid hormone levels are low in the overloaded heart tissue in a local hypothyroid state, with low levels of deiodinase 1 and deiodinase 2. Although deiodinase 3 levels in a normal heart are generally low, in cardiomyopathy deiodinase 3 activity is increased to decrease energy turnover and oxygen consumption.[7]

Hypothyroidism is a disease diagnosed by decreased levels of serum thyroxine (T₄). Presentation in adults leads to decreased metabolism, increased weight gain, and neuropsychiatric complications.[21] During development, hypothyroidism is considered more severe and leads to neurotoxicity as cretinism or other human cognitive disorders,[22] altered metabolism and underdeveloped organs. Medication and environmental exposures can result in hypothyroidism with changes in deiodinase enzyme activity. The drug iopanoic acid (IOP) decreased cutaneous cell proliferation by inhibition of deiodinase enzyme type 1 or 2 reducing the conversion of T₄ to T₃. The environmental chemical DE-71, a PBDE pentaBDE brominated flame retardant decreased hepatic deiodinase I transcription and enzyme activity in neonatal rats with hypothyroidism.[23]

In vitro, including cell culture experiments, deiodination activity is determined by incubating cells or homogenates with high amounts of labeled thyroxine (T₄) and required cosubstrates. As a measure of deiodination, the production of radioactive iodine and other physiological metabolites, in particular T₃ or reverse T₃, are determined and expressed (e.g. as fmol/mg protein/minute).[24][25]

In vivo, deiodination activity is estimated from equilibrium levels of free T₃ and free T₄. A simple approximation is T₃/T₄ ratio,[26] a more elaborate approach is calculating sum activity of peripheral deiodinases (GD) from free T₄, free T₃ and parameters for protein binding, dissociation and hormone kinetics.[27][28] In atypical cases, this last approach can benefit from measurements of TBG, but usually only requires measurement of TSH, fT3 and fT4, and as such has no added laboratory requirements besides the measurement of the same.

• Iodotyrosine deiodinase
• Selenium, section Evolution in biology

• Deiodinase at the US National Library of Medicine Medical Subject Headings (MeSH)